Search Results

You are looking at 1 - 10 of 330 items for :

  • Refine by Access: All x
Clear All
Full access

Szu-Chun Yang, Yi-Chen Yeh, Yi-Lin Chen, and Chao-Hua Chiu

Cancer, 3 patients with newly diagnosed metastatic lung adenocarcinoma are recommended to be tested for mutations in 8 driver genes, including EGFR , ALK , ROS1 , BRAF , RET , MET , NTRK , and KRAS , because FDA-approved therapies are available

Full access

Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz, and Sharon Spencer

References 1 Mendelsohn J . Targeting the epidermal growth factor receptor for cancer therapy . J Clin Oncol 2002 ; 20 : 1s – 13s . 2 Castillo L Etienne-Grimaldi MC Fischel JL . Pharmacological background of EGFR

Full access

Zi-Xian Wang, Hao-Xiang Wu, Ming-Ming He, Ying-Nan Wang, Hui-Yan Luo, Pei-Rong Ding, Dan Xie, Gong Chen, Yu-Hong Li, Feng Wang, and Rui-Hua Xu

–epidermal growth factor receptor (EGFR) agents (Cet/Pani) compared with chemotherapy alone in relation to PTL in patients with RAS wt mCRC. Patients and Methods This meta-analysis was reported in accordance with PRISMA guidelines. 20 Study Selection and Data

Full access

Jeremy D. Kratz, Nataliya V. Uboha, Sam J. Lubner, Daniel L. Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A. Matkowskyj, Noelle K. LoConte, and Dustin A. Deming

chemotherapy and targeted agents depending on distinct molecular profiles. Antibodies targeting epidermal growth factor receptor (EGFR), including cetuximab and panitumumab, have shown clinical utility in the late-line setting. 3 , 4 Defining populations most

Full access

Noman Ashraf, Nishi Kothari, and Richard Kim

mutations, and how these data may impact clinical decision-making Identify established predictive markers for cetuximab and panitumumab Discuss the clinical implications of data regarding potential new biomarkers for anti-EGFR therapy Colorectal

Full access

Jon Apple, Rahul Shenolikar, Kevin De Silva, Ping Sun, and Alexander Spira

Background : Current national guidelines recommend epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line (1L) for EGFR mutated metastatic non-small cell lung cancer (EGFRm mNSCLC) patients. Depending on the

Full access

Rogerio A. Lilenbaum and Leora A. Horn

The identification of molecular targets and the development of agents to treat those targets has changed the paradigm for the management of non–small cell lung cancer (NSCLC). “The progress in NSCLC has been absolutely amazing. EGFR and KRAS

Full access

Joshua K. Sabari, John V. Heymach, and Beth Sandy

mutation status. 2 , 3 The most frequently altered genes in NSCLC are EGFR (10%–35%), KRAS (25%–30%), FGR (20%), ALK (3%–7%), MET (2%–4%), BRAF (1%–3%), ROS1 (1%–3%), and RET (1%–3%). 2 , 3 For many of the molecular subsets, including

Full access

Ammar Sukari, Misako Nagasaka, and Erin Wakeling

-capture–selected libraries are sequenced to high uniform depth (targeting >500x coverage by non-PCR duplicate read pairs, with >99% exons at coverage >100x) on the Illumina HiSeq2000 sequencing platform. 1 Genomic DNA isolation and EGFR T790M real-time PCR was performed

Full access

Philip E. Lammers, Christine M. Lovly, and Leora Horn

testing of exons 18-21 of the epidermal growth factor receptor ( EGFR) gene performed at an outside institution revealed the presence of both an EGFR L858R missense mutation in exon 21 and a T790M point mutation in exon 20. His local oncologist was